Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Inclisiran for Patients With Coronary Heart Disease in China
NCT06941792Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 4 trial of inclisiran in coronary heart disease (CHD), sponsored by Novartis. Started Jun 2025; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT06941792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941792.